As bacteriophages transition from research tools to real-world therapeutics and biocontrol solutions, the role of the phage CDMO (Contract Development and Manufacturing Organization) has become pivotal. Unlike standard biologics such as monoclonal antibodies or recombinant proteins, phages are living biological entities with unique life cycles, host dependencies, and manufacturing constraints. Scaling their production requires expertise […]